Pharmaceuticals in Thoughts from the Centre

Forging a new path to commercialization for cell and gene therapies

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Deloitte-uk-green-trees-and-grass

This week’s blog, by Greg Reh from the US firm, first appeared on the US Center for Health Solutions blog site. The blog features Greg’s commentary on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Continue reading

Posted on 16/08/2019 | 0 Comments

Why improving inclusion and diversity in clinical trials should be a research priority

By Karen Taylor, Director, Centre for Health Solutions

Diversity

Several weeks ago I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit sufficient trial participants from important demographic groups, especially women, racial and ethnic minorities, and the elderly. As a result, the outcomes seen in clinical trials are likely to be unrepresentative of the patient outcomes in the real world.

Continue reading

Posted on 08/08/2019 | 0 Comments

Deal breaker? Mitigating cyber risk in life sciences M&A

By Nadeem Mohammed, Deloitte MCS Limited

Lock

Imagine the scene: it’s Friday night, eight senior executives at one of the world’s largest companies are sitting around a private dining table at a swanky city restaurant. They’re there to celebrate the closure of a transaction they’ve been toiling over for the past 12 months. You’re the Deal Lead, and you’ve just taken a congratulatory phone call from the Chief Executive – the Board are delighted with the acquisition, which will now be at the heart of the company’s growth strategy. You’ve given blood, sweat and tears on this – you raise a glass towards the table and take a quiet moment to reflect on what is surely a career defining moment.

Continue reading

Posted on 26/07/2019 | 0 Comments

Safety first: Technology and analytics could help transform pharmacovigilance

By Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP

Safety

This week's blog, by Kelly Traverso from the US firm, first appeared on the US Center for Health Solutions blog site. The blog looks at how utilising automation can help transform pharmacovigilance.

Continue reading

Posted on 12/07/2019 | 0 Comments

2019 Human Capital Trends: Reinvent with a human focus – the implications for the Life Sciences industry

By Shivani Maitra, Partner, Consulting

Hctrends

This time of year is always a highlight for me as it sees the publication of our annual Global Human Capital Trends report, based on the views of 10,000 survey respondents across 119 countries. This year’s findings reinforce the views of colleagues in the Life Sciences (LS) team, specifically that LS organisations need to rethink the workforce experience, adapt to a more diverse workforce and transform their approach to leadership development.

Continue reading

Posted on 28/06/2019 | 0 Comments

How biopharma R&D can thrive in the UK: Insights from an expert panel discussion

By Matthew Thaxter, Analyst, Centre for Health Solutions

Pharma

Following the launch of our ninth annual report ‘Unlocking R&D productivity: Measuring the return from pharmaceutical innovation 2018’, we hosted a panel discussion in London to explore how innovation in the wider R&D ecosystem can unlock R&D productivity. Our panel of experts comprising representatives from big pharma, a small innovative biotech company, the ABPI and the Medicines Discovery Catapult discussed a wide range of topics including: the UK healthcare ecosystem, government policies in the UK aimed at supporting the life sciences industry, the evolving skills and talent agenda and the role of regulators in encouraging innovation. Below are some of the key highlights from the discussion.

Continue reading

Posted on 21/06/2019 | 0 Comments

Launching innovative biopharma in China: Market access, reimbursement and digital health care

By Mark Steedman, PhD, Manager, Centre for Health Solutions

Rocket

In March, Deloitte colleagues David Xie and Xiaofeng Li published the article Gain the edge in a fast moving market, introducing a series of articles on ‘Launching innovative biopharma in China’. This introductory article was the subject of a previous blog that we published in February.1 This week’s blog explores the findings in the next two articles in the series: A new view on market access and reimbursement, examining innovative alternative reimbursement opportunities in the public and self-pay markets; and A new view on China’s digital health care, evaluating how product launches can target digitally savvy consumers.

Continue reading

Posted on 12/04/2019 | 0 Comments

Future of life sciences regulation webcast: key takeaways

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Our November 2018 report - A bold future for life sciences regulation: Predictions 2025 - highlighted some of the challenges presented by today’s complex and fragmented life sciences regulatory landscape and the difficulties facing regulators and industry in ensuring efficacy and patient safety while keeping pace with changes in medicine, science and technology.1 Since publication, we have had insightful discussions with clients around our predictions and last week held an interactive webinar, where we explored how industry, regulators and patients can succeed together. The webinar included three guest speakers, representing each of these perspectives, and the discussion comprised an overview of the prediction followed by a polling question and the discussion among the panellists. This week’s blog shares the highlights of the webinar.2

Continue reading

Posted on 29/03/2019 | 0 Comments

Addressing the gender imbalance in life sciences today to secure a better tomorrow

By Debi Rhodes, COO & Clients & Industries Lead, Life Sciences & Healthcare

Untitled-11

Today, Friday 8th March marks the annual celebration of International Women’s Day with the theme, Balance for Better. I couldn’t help but question what this day really means to me? How is it important to my future, that of my children, to business and society as a whole, particularly when we consider the Future of Work and the impact of AI and new technologies on the skills and talent that will be needed in tomorrow’s world? Given my tendency for cynicism, I also questioned how the future might impact the issue of gender equality?

Continue reading

Posted on 08/03/2019 | 0 Comments

Five strategies that could help biopharma firms get more ROI bang for their R&D buck

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Pharma

This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on the findings from our 2018 Measuring the return from pharmaceutical innovation 2018 report, and what strategies pharma can use to improve their return on investment from R&D.

Continue reading

Posted on 01/02/2019 | 0 Comments